SIR2501
/ Sironax
- LARVOL DELTA
Home
Next
Prev
1 to 5
Of
5
Go to page
1
October 07, 2025
Dose-dependent and robust target engagement of a novel brain penetrant SARM1 inhibitor (SIR2501) in healthy adult participants
(Neuroscience 2025)
- "SIR2501 demonstrated dose-dependent and robust target engagement ex vivo in stimulated PBMCs, indicating it is a potent inhibitor of SARM1 and suggesting its therapeutic potential to modulate SARM1 NADase activity in humans to protect against axonal degeneration. These findings support the further evaluation of SIR2501 in clinical development, including the treatment of ALS, and prevention or lessening the severity of CIPN."
Clinical • Amyotrophic Lateral Sclerosis • CNS Disorders • Vascular Neurology
July 18, 2025
Phase 1 Study to Investigate SIR2501 in Healthy Adult Participants
(ANZCTR)
- P1 | N=112 | Completed | Sponsor: Sironax Australia Pty Ltd | Recruiting ➔ Completed
Trial completion • CNS Disorders
April 22, 2025
Company Milestones: Vitalon Announces Completion of Phase I Clinical Trial of SIR2501 [Google translation]
(bydrug.pharmcube.com)
- "Recently, SIR2501, a candidate drug for neurological diseases independently developed by Vitallon...successfully completed the Phase I clinical trial in healthy subjects. The trial is a randomized, double-blind, placebo-controlled, single and multiple dose escalation study designed to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of SIR2501 in healthy subjects....The Vitalon team is excited about the results of the Phase I trial of SIR2501..."
Trial completion • CNS Disorders
June 28, 2024
Phase 1 Study to Investigate SIR2501 in Healthy Adult Participants
(ANZCTR)
- P1 | N=112 | Recruiting | Sponsor: Sironax Australia Pty Ltd | Not yet recruiting ➔ Recruiting | Initiation date: May 2024
Enrollment open • Trial initiation date • CNS Disorders
May 03, 2024
Phase 1 Study to Investigate SIR2501 in Healthy Adult Participants
(ANZCTR)
- P1 | N=112 | Not yet recruiting | Sponsor: Sironax Australia Pty Ltd
New P1 trial • CNS Disorders
1 to 5
Of
5
Go to page
1